NKTR vs NVST · rev $21.0M vs P/E 56, rev $1.44B
Nektar Therapeutics (NKTR) versus Envista Holdings Corp (NVST) — a side-by-side from cached financials, not a winner call.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Envista Holdings Corp (NVST) is a medical instruments & supplies company listed on US.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
Latest reported NVST revenue for 2026-07-03 was $1.44B. Net income was $92.4M. NVST currently screens at market cap $3.72B and trailing P/E 55.8.
NKTR currently screens at market cap $307.2M. NVST currently screens at market cap $3.72B and trailing P/E 55.8.
Not investment advice. Open the NKTR and NVST stock pages for the full models.
Not investment advice.